Drug Profile
MYK 581
Alternative Names: MYK-581Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator MyoKardia
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Cardiac myosin inhibitors; Myosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertrophic cardiomyopathy
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Hypertrophic cardiomyopathy in USA (IV)
- 23 Aug 2023 Discontinued - Preclinical for Hypertrophic cardiomyopathy in USA (PO)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Hypertrophic-cardiomyopathy in USA (PO)